Investor Claims Against Drug Maker Over COVID-19 Therapy Deemed Insufficient
SAN DIEGO — A federal judge in California on Nov. 18 ruled that the lead plaintiff in a securities class action lawsuit against a clinical-stage biopharmaceutical company and certain of its...To view the full article, register now.
Already a subscriber? Click here to view full article